Compare · ACON vs ILMN
ACON vs ILMN
Side-by-side comparison of Aclarion Inc. (ACON) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 7186.2x ACON ($5.6M).
- ILMN has been more active in the news (8 items in the past 4 weeks vs 3 for ACON).
- ILMN has more recent analyst coverage (25 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $5.6M
- $40.46B
- 1M return
- -27.59%
- -
- 1Y return
- -76.58%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2000
- News (4w)
- 3
- 8
- Recent ratings
- 0
- 25
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ACON
- Aclarion to Present at the 20th Annual LD Micro Main Event
- Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
- Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
- Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
- Director Williams Amanda M bought $15,990 worth of shares (5,857 units at $2.73), increasing direct ownership by 29% to 25,857 units (SEC Form 4)
- CFO Gould Gregory A bought $24,500 worth of shares (10,000 units at $2.45), increasing direct ownership by 20% to 60,000 units (SEC Form 4)
- Chief Executive Officer Ness Brent bought $12,091 worth of shares (5,234 units at $2.31), increasing direct ownership by 5% to 111,534 units (SEC Form 4)
- Director Bond Ryan bought $50,059 worth of shares (21,122 units at $2.37), increasing direct ownership by 38% to 76,122 units (SEC Form 4)
- Director Wesemann William bought $5,031 worth of shares (2,150 units at $2.34), increasing direct ownership by 10% to 23,713 units (SEC Form 4)
- Director Neal David K bought $18,000 worth of shares (7,500 units at $2.40), increasing direct ownership by 33% to 30,002 units (SEC Form 4)
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)